MedImmune strengthens portfolio with acquisition of Amplimmune

MedImmune, AstraZeneca’s global biologics arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held company focused on developing novel therapeutics in cancer immunology. MedImmune will acquire 100% of Amplimmune’s shares for $225m plus deferred milestone payments of up to $275m.

The acquisition will bolster MedImmune’s oncology pipeline by obtaining multiple early-stage assets for its immune-mediated cancer therapy (IMT-C) portfolio, including AMP-514, an anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb). AMP-514 is currently in late-stage pre-clinical development with the aim of an investigational new drug (IND) filing before the end of 2013. Other Amplimmune assets include multiple preclinical molecules targeting the B7 pathways.

“MedImmune’s focus on harnessing the power of the patient’s own immune system to fight cancer will be complemented by Amplimmune’s innovative work in this area. It will allow us to strengthen our arsenal of potential cancer therapies,” said Dr. Bahija Jallal, Executive Vice President, MedImmune. “We are excited to be working with the Amplimmune team to help find new treatments to address areas of unmet medical need.”